VginsmsBOTOX: Injection of Botox in the Perineal Muscles in Resistant Cases of Vaginal Spasm

Sponsor
Abdel-Maguid Ramzy (Other)
Overall Status
Completed
CT.gov ID
NCT01859507
Collaborator
(none)
32
1
1
13.9
2.3

Study Details

Study Description

Brief Summary

During the first visit, the couple will be acquainted with their condition. This will include the epidemiology of their condition, some sex education tips, as well as the therapeutic modalities available. This is followed by short description of the protocol. In the procedure room, each patient will be examined to determine the degree of vaginismus and classify her condition according to Lemont's classification as modified by Pacik, from 1 to 5. In the same or subsequent sessions, surface anesthesia of the area of injection followed by ice packs is used before the BOTOX is injected into the muscle.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

In the first session, proper history taking includes the difficulties they are facing, and the measures taken to solve it whether medical or folk treatment. Proper counseling of the couple to describe the new modality including the BOTOX injection and subsequent dilatation sessions. Proper informed consent forms will be signed. Therapy sessions will starts with the gentle informed approach to the genital area to gain trust of the patient. This is followed by the digital vaginal examination of the patient to determine the degree of spasm and the muscle(s) involved.

The patient will be asked to lie down comfortably on the examination table in the lithotomy position. Her husband is allowed to stand on her left shoulder side and may be allowed to hold her hand. We started by sterilizing the perineal area and injection site in the vaginal introitus using povidone iodine solution. The patient is warned effectively before each step of the procedure and what to expect as regards pain. We used surface (Xylocaine gel) anesthesia half an hour before the injection.We did not use local anesthetic infiltration injections at the site of BOTOX injection. In addition we used ice packs, pre-prepared in a surgical latex glove finger, on the perineum and introitus before the injection of BOTOX to act as a counter irritant. However in advanced cases of Vaginismus (V4-5), we used general intravenous anesthesia

We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX. We only did one skin puncture, and used that to radially injecting the intended area by changing the direction of the tip of the needle. We found this much less painful to the patient. The injection site will be monitored by the other free hand index and thumb. Following the withdrawal of the needle from the muscle, we distributed the bolus of BOTOX uniformly within the muscle digitally using an arc fashion massage of the introitus. We applied pressure, whenever needed to stop the bleeding from the injection site.

Following the procedure, we instruct the patient to do Kegel exercises as much as 100 contractions or more over 48 hours. This will help in distributing the BOTOX within the muscles as well as recognition of the patient of the whereabouts of the muscles involved in vaginismus. We followed up on our patients daily by phone calls for 4 days following the procedure for possible adverse effects.

Thereafter, the patient will be instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators covered by lubricated condoms. We prepared the vaginal introitus by the use K-Y jelly for lubrication of the dilators. The patient is introduced to the dilator and allowed to hold it in her hand, for size and feel, prior to its introduction into her vagina. During each session the patient will be asked to lie down on the examination table in the lithotomy position, relax and feel comfortable. The husband may stand beside her and may hold her hand. In the initial phase of the dilatation procedure we start with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, in each session, and increase the size gradually. We always start by the smaller size and move up size wise. At later sessions we allow the patient herself with its introduction into the vagina using only her tactile sense, with no visual aid or doctor instructions, covering her thighs with sheets to feel more private. She is asked to report the termination of the introduction or difficulties she is facing. Verbal support is always and repeatedly used. In case of difficulty, the doctor does not offer to help and ask the patient to try on her own once more. This helps her to be proactive and gain control of the procedure. They usually succeed to carry on the procedure on their own. The couple will be instructed not to have trials of intercourse before the patient uses dilator number 4 comfortably.

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Study of the Effectiveness and Safety of Clostridium Botulinum Type A Neurotoxin Complex Injection in the Perineal Muscles in Resistant Cases of Vaginismus
Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Mar 1, 2014
Actual Study Completion Date :
Mar 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: BOTOX group

Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.

Drug: Botox
In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
Other Names:
  • Clostridium Botulinum type A neurotoxin complex
  • Outcome Measures

    Primary Outcome Measures

    1. Success of Repeated Penetration of the Penis Through the Vaginal Introitus Into the Vagina Without or With Acceptable Pain [Up to four weeks following the last session of the vaginal dilatation.]

      The primary outcome will be assessed by the couple. The couple is allowed to visit for follow up in a 4 weeks' time. Our inquiry is on the success of full and repeated penetration of the penis through the vaginal introitus into the vagina without or with acceptable pain. An acceptable outcome will be at least twice weekly successful sexual relationship that was completed without premature interruption from either partners.

    Secondary Outcome Measures

    1. Successful Sexual Relationship [Within twelve months after the Botox injection]

      The level of comfort by the couple. The secondary outcome will be assessed by the couple. The couple is allowed to visit for follow up every three months for twelve months. Our inquiry is on the success of full and repeated penetration of the penis through the vaginal introitus into the vagina without or with acceptable pain. An acceptable outcome will be at least twice weekly successful sexual relationship that was completedwithout premature interruption from either partners.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 44 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • cases with resistant vaginismus
    Exclusion Criteria:
    • cases with congenital anomalies in the lower female genital tract

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 AbdelMaguid Ramzy Cairo Egypt 11341

    Sponsors and Collaborators

    • Abdel-Maguid Ramzy

    Investigators

    • Principal Investigator: AbdelMaguid I Ramzy, MD, Cairo University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Abdel-Maguid Ramzy, Prof. Of OB. GYN.,, Cairo University
    ClinicalTrials.gov Identifier:
    NCT01859507
    Other Study ID Numbers:
    • ramzy9501
    First Posted:
    May 22, 2013
    Last Update Posted:
    Apr 14, 2015
    Last Verified:
    Apr 1, 2015
    Keywords provided by Abdel-Maguid Ramzy, Prof. Of OB. GYN.,, Cairo University
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title Botox
    Arm/Group Description Injection of Clostridium Botulinum type A neurotoxin complex in the perineal muscles in resistant cases of vaginismus. Trade Name: BOTOX 100 units vial Injection of Botox in the perineal muscles in resistant cases of vaginismus
    Period Title: Overall Study
    STARTED 32
    COMPLETED 28
    NOT COMPLETED 4

    Baseline Characteristics

    Arm/Group Title Botox
    Arm/Group Description Injection of Clostridium Botulinum type A neurotoxin complex in the perineal muscles in resistant cases of vaginismus. Trade Name: BOTOX 100 units vial Injection of Botox in the perineal muscles in resistant cases of vaginismus
    Overall Participants 28
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    29.25
    (4.85)
    Sex: Female, Male (Count of Participants)
    Female
    28
    100%
    Male
    0
    0%
    Region of Enrollment (participants) [Number]
    Egypt
    28
    100%

    Outcome Measures

    1. Primary Outcome
    Title Success of Repeated Penetration of the Penis Through the Vaginal Introitus Into the Vagina Without or With Acceptable Pain
    Description The primary outcome will be assessed by the couple. The couple is allowed to visit for follow up in a 4 weeks' time. Our inquiry is on the success of full and repeated penetration of the penis through the vaginal introitus into the vagina without or with acceptable pain. An acceptable outcome will be at least twice weekly successful sexual relationship that was completed without premature interruption from either partners.
    Time Frame Up to four weeks following the last session of the vaginal dilatation.

    Outcome Measure Data

    Analysis Population Description
    multiple penetration with minimal pain as informed by the couple during their follow up sessions 4 weeks after the completion of the dilatation sessions
    Arm/Group Title Botox
    Arm/Group Description Injection of Clostridium Botulinum type A neurotoxin complex in the perineal muscles in resistant cases of vaginismus. Trade Name: BOTOX 100 units vial Injection of Botox in the perineal muscles in resistant cases of vaginismus
    Measure Participants 28
    Number [participants]
    28
    100%
    2. Secondary Outcome
    Title Successful Sexual Relationship
    Description The level of comfort by the couple. The secondary outcome will be assessed by the couple. The couple is allowed to visit for follow up every three months for twelve months. Our inquiry is on the success of full and repeated penetration of the penis through the vaginal introitus into the vagina without or with acceptable pain. An acceptable outcome will be at least twice weekly successful sexual relationship that was completedwithout premature interruption from either partners.
    Time Frame Within twelve months after the Botox injection

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title BOTOX Group
    Arm/Group Description Injection of BOTOX 100 units vial as a single dose intramuscular in the perineal muscles. Proper informed consent forms will be signed. In most of the cases we use local anesthetic before injection. However in V4 and 5 we resort to general anesthesia. We followed up the patient by phone calls daily for possible adverse effects following the procedure for 4 days, which is the interval allowed for the BOTOX to be fully effective. The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators covered by lubricated condoms. We start each session with the appropriate size of the dilator according to the capacity of the introitus and increase the size gradually thereafter. We proceed till the patient uses the largest dilator with no or limited pain. The patient is then advised then to try to have intercourse and report back to us. Botox: In the first session, proper histor
    Measure Participants 28
    Number [participants]
    28
    100%

    Adverse Events

    Time Frame Up to 12 months
    Adverse Event Reporting Description 2 participants who started the study could not be reached for adverse event monitoring. Participants were monitored for 4 days closely for adverse events related to the injection and then via phone for a year for any additional adverse events.
    Arm/Group Title Botox
    Arm/Group Description Injection of Clostridium Botulinum type A neurotoxin complex in the perineal muscles in resistant cases of vaginismus. Trade Name: BOTOX 100 units vial Injection of Botox in the perineal muscles in resistant cases of vaginismus
    All Cause Mortality
    Botox
    Affected / at Risk (%) # Events
    Total / (NaN)
    Serious Adverse Events
    Botox
    Affected / at Risk (%) # Events
    Total 0/30 (0%)
    Other (Not Including Serious) Adverse Events
    Botox
    Affected / at Risk (%) # Events
    Total 0/30 (0%)

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    All Principal Investigators ARE employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Abdelmaguid Ramzy
    Organization Cairo University. Department of Obstetrics and Gynecology
    Phone +201008606060
    Email amramzy@gmail.com
    Responsible Party:
    Abdel-Maguid Ramzy, Prof. Of OB. GYN.,, Cairo University
    ClinicalTrials.gov Identifier:
    NCT01859507
    Other Study ID Numbers:
    • ramzy9501
    First Posted:
    May 22, 2013
    Last Update Posted:
    Apr 14, 2015
    Last Verified:
    Apr 1, 2015